Veozah (fezolinetant), a non-hormonal drug hailed as a breakthrough for managing menopausal hot flashes, was approved by the FDA in May 2023. Marketed as a safe alternative to hormone replacement therapies, Veozah quickly gained popularity among women seeking relief from debilitating vasomotor symptoms. However, the celebration was short-lived. Reports of severe liver injuries linked to the drug began to surface, prompting FDA interventions and spurring a wave of lawsuits.
Patients allege that Veozah’s manufacturer, Astellas Pharma, failed to adequately warn consumers and healthcare providers about the significant risks associated with its use. As the number of affected individuals grows, legal action is shedding light on the dangers of insufficient drug testing and corporate negligence.
Reverse Chronological Timeline of Key Events